Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Caroline Scherer

Clinical Cardiac Electrophysiology Philadelphia, PA Physician Assistant

NPI 1780289215 CMS profile 8793208

3400 Civic Center Blvd, Philadelphia, PA 19104

Open in the dashboard

General payments

$2,211

61 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Caroline Scherer of Philadelphia, PA is reported in the CMS Open Payments database as having received $2,211 across 61 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 12th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $301 7
2024 General $631 19
2023 General $1,094 26
2022 General $149 7
2021 General $36 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Caroline Scherer
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Caroline Scherer were reported at $301. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Caroline Scherer Clinical Cardiac Electrophysiology median Middle half National median
2019 $0 $2,361 $585–$8,260 $163
2020 $0 $993 $247–$4,351 $114
2021 $36 $1,185 $326–$4,739 $132
2022 $149 $2,073 $554–$6,789 $149
2023 $1,094 $2,568 $759–$8,159 $160
2024 $631 $2,557 $703–$7,403 $164
2025 $301 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $542 10 payments
  2. Janssen Pharmaceuticals, Inc $526 16 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $406 8 payments
  4. Philips Electronics North America Corporation $253 10 payments
  5. Abbott Laboratories $155 2 payments
  6. Impulse Dynamics (USA) Inc. $65 2 payments
  7. E.R. Squibb & Sons, L.L.C. $61 4 payments
  8. Biotronik Inc. $49 2 payments
  9. Inspire Medical Systems, Inc. $40 1 payment
  10. Medtronic, Inc. $36 2 payments
  11. Other $78 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,175 59 payments
  2. Education $36 2 payments
Products named General payments · program years 2021–2025
  1. XARELTO $526 16 payments
  2. LifeVest $406 8 payments
  3. WATCHMAN FLX $318 5 payments
  4. WATCHMAN Access System $208 4 payments
  5. AVEIR $121 1 payment
  6. (5044) MCOT $79 3 payments
  7. (CK4) MCOT $72 3 payments
  8. Extended Holter $63 2 payments
  9. INSPIRE $40 1 payment
  10. (5050) Extended Holter $39 2 payments
  11. Other $391 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

606

Median for Physician Assistant: 241

Drug cost

$303,201

Median for Physician Assistant: $4,110

Branded share of claims

46.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 178 $175,912
Xarelto Rivaroxaban Brand 70 $88,077
Dofetilide Generic 69 $22,989
Quinidine Gluconate Generic 15 $7,681
Propafenone Hcl Er Propafenone Hcl Brand 12 $2,922
Metoprolol Succinate Generic 154 $2,713
Amiodarone Hcl Generic 27 $886
Sotalol Sotalol Hcl Brand 23 $666
Flecainide Acetate Generic 11 $620
Mexiletine Hcl Generic 11 $488

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $136
$136 70 —
ELIQUIS
  • PFIZER INC. $15
$15 178 —
NURTEC ODT
  • PFIZER INC. $8
$8 — —
PAXLOVID
  • PFIZER INC. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

61 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record